All In MedTech

Regulatory pathways

The De Novo pathway: how novel low-to-moderate risk devices reach market

De Novo FDA classification explained: when a De Novo request is used instead of a 510(k), what it must show, how review works, and what a grant creates.

By the All In MedTech editorial team · Published November 19, 2026 · 6 min read

The De Novo pathway lets FDA classify a new kind of medical device into Class I or Class II when there is no existing device to compare it with. Without it, any device found not substantially equivalent to a predicate would be Class III by default and need full premarket approval, even if its risks were modest. A granted De Novo authorizes the device for marketing and creates a new classification regulation for its type.

This post covers where De Novo came from, when to use it, what a request must show, how the review runs, and why the first De Novo in a category matters to everyone who follows.

Why De Novo exists

The Medical Device Amendments of 1976 set up the three-class system. A device that was not substantially equivalent to a device on the market before May 28, 1976, or to one cleared since, was automatically placed in Class III under section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act. That meant genuinely new but low-risk devices faced the same PMA burden as implanted heart devices, unless someone petitioned for reclassification.

Congress added the De Novo process in the Food and Drug Administration Modernization Act of 1997, now section 513(f)(2) of the Act. At first, a sponsor had to receive a "not substantially equivalent" decision on a 510(k) before asking for De Novo. The Food and Drug Administration Safety and Innovation Act of 2012 added a direct route, so sponsors who already knew no predicate existed could skip the 510(k) step. The 21st Century Cures Act of 2016 made further changes.

FDA codified its procedures in a final rule published October 5, 2021, in 21 CFR Part 860, subpart D. The rule took effect January 3, 2022, and sets out the content of a request, how FDA accepts it, and the grounds for granting or declining.

When De Novo is the right pathway

Under 21 CFR 860.200, a De Novo request may be submitted in two situations:

  1. After an NSE decision. FDA has found the device not substantially equivalent through a 510(k), often because there is no predicate with the same intended use or because the technology raises different questions of safety and effectiveness.
  2. Directly. The sponsor determines there is no legally marketed device on which to base a substantial equivalence claim and files De Novo without a 510(k) first.

Either way, two conditions have to hold:

  • No suitable predicate. If the device type is already classified, or a predicate exists, the 510(k) or PMA pathway applies instead. One ground for declining in 21 CFR 860.260 is that the device is of a type that has already been classified.
  • Risk low enough for Class I or II. General controls alone, or general and special controls, must be able to provide reasonable assurance of safety and effectiveness. If no realistic set of controls could do that, the device belongs in Class III and needs a PMA.

FDA encourages sponsors to use a Pre-Submission to discuss whether De Novo fits and what data FDA will expect. For a side-by-side view of all three routes, see 510(k) vs De Novo vs PMA.

What a De Novo request must show

A 510(k) argues by comparison. A De Novo request has to make the case on its own terms, closer in spirit to a PMA but scaled to a lower-risk device. The content requirements in 21 CFR 860.220 include, among other items:

  • a description of the device, its intended use and indications for use,
  • a summary of prior submissions for the device, including any NSE decision,
  • a classification recommendation, Class I or Class II, with the reasons,
  • an identification of the risks to health the device presents and the mitigations for each,
  • for a Class II recommendation, proposed special controls that would address those risks,
  • the nonclinical and, where needed, clinical data supporting safety and effectiveness,
  • a benefit-risk discussion showing that probable benefits outweigh probable risks, and
  • proposed labeling.

The risk and mitigation analysis is the core. FDA wants to see each identified risk paired with a control: a performance test, a labeling requirement, a biocompatibility evaluation, a software validation requirement and so on. Those pairings often become the special controls in the eventual classification regulation.

Since October 1, 2025, FDA has required most De Novo requests to be submitted electronically using its eSTAR template, as it already did for 510(k)s.

How the review works

FDA's process has three broad stages:

  1. Acceptance review. FDA checks that the request is administratively complete under 21 CFR 860.230. With eSTAR, much of this is built into the template, and FDA says technical screening should happen within 15 calendar days of receipt. An incomplete request goes on hold, and if the missing material does not arrive within 180 days, the request is treated as withdrawn.
  2. Substantive review. Reviewers assess the evidence, the risk analysis and the proposed controls, and may request additional information. FDA may also inspect the manufacturer.
  3. Decision. FDA either grants or declines the request by written order.

The statute directs FDA to make a decision within 120 days of receiving a request, while user fee performance goals under the Medical Device User Fee Amendments (MDUFA) track how quickly FDA actually decides. Those goals and the De Novo user fee are revised with each MDUFA agreement, so check FDA's MDUFA page for current figures.

What a grant creates

A De Novo grant does more than authorize one product. Under 21 CFR 860.260, when FDA grants a request it publishes notice of the classification in the Federal Register, and it adds a new classification regulation to the CFR. That regulation:

  • names and describes the new generic device type,
  • assigns it to Class I or Class II,
  • lists any special controls, and
  • states whether the type is exempt from 510(k).

FDA also assigns a new three-letter product code. From then on, the granted device is a legally marketed predicate. A competitor with a device of the same type, meeting the same special controls, can file an ordinary 510(k) citing it. That is why the first company in a new category often carries the De Novo cost, and followers come in more cheaply. FDA publishes a decision summary for each granted request, which is one of the best public descriptions of the evidence FDA found sufficient.

When FDA declines

If FDA declines, the order explains the deficiencies and each ground that applied. Common reasons include insufficient data, risks that the proposed controls do not adequately mitigate, or a finding that the device actually fits an existing classification. Options after a decline include addressing the deficiencies and submitting a new request, filing a 510(k) if a predicate turns out to exist, or pursuing a PMA if the device really needs Class III controls.

De Novo in context

A few points help put De Novo in perspective:

  • It is a classification action, not only a marketing authorization. That makes the special controls important to the whole category, not just the sponsor.
  • It sits between 510(k) and PMA in evidence burden. It does not require a predicate, but it does not require the level of evidence of a PMA for a life-sustaining device either.
  • Breakthrough devices often use it. Many novel digital health, diagnostic and therapeutic devices with breakthrough designation reach market through De Novo. See /breakthrough.

For background on how classes, regulations and product codes fit together, read FDA device classes and product codes explained. FDA's own De Novo classification request page links to the current guidance documents and the eSTAR template.

Frequently asked questions

What is a De Novo request?
It is a request asking FDA to classify a novel device with no legally marketed predicate into Class I or Class II, instead of the automatic Class III that would otherwise apply.
What is the difference between De Novo and 510(k)?
A 510(k) compares a device to an existing predicate, while De Novo is used when no predicate exists and asks FDA to create a new classification for the device type.
Can a De Novo device be used as a predicate?
Yes. Once FDA grants a De Novo request, the device can serve as a predicate for later 510(k) submissions for devices of the same type.
Where are the De Novo rules?
The statutory basis is section 513(f)(2) of the FD&C Act, and FDA's procedures are in 21 CFR Part 860, subpart D, effective January 3, 2022.

For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.

Keep reading